ClinicalTrialsFinder

Relapsed or Refractory B-cell Malignancies Clinical Trials in Pamplona

1 recruitingPamplona, Spain

Showing 1–1 of 1 trials

Recruiting
Phase 1

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.85 enrolled9 locationsNCT06980116